Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.33 |
| ▸ | CCR5 | P51681 | 2/20 | 0.33 |
| ▸ | CCR8 | P51685 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.31 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.31 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.31 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951146 | 1.00 | CCR1 (0.33) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL16225784 | 0.81 | HPGD (0.43) | NOS3NOS2ALDH1A1MAPT | |
| SCHEMBL29956414 | 0.81 | HPGD (0.43) | NOS3NOS2ALDH1A1MAPT | |
| SCHEMBL29956241 | 0.81 | ENPP2 (0.39) | ENPP2CA1CA2GAAORAI1 | |
| SCHEMBL5039573 | 0.81 | ENPP2 (0.39) | ENPP2CA1CA2GAAORAI1 | |
| SCHEMBL29950703 | 0.79 | NFE2L2 (0.33) | CCR1CCR5CCR8ENPP2CA1 | |
| SCHEMBL16110848 | 0.75 | CCR1 (0.38) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL29954504 | 0.75 | CCR1 (0.38) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL26361648 | 0.75 | MAOA (0.41) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL29954528 | 0.75 | ALDH1A1 (0.36) | GAAAPLNRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-17 | — | — | US | disclosed |
| US-11958865-B1 | Leucine-rich repeat kinase 2 (LRRK2) inhibitors | H. LUNDBECK A/S (DK) | 2024-04-16 | — | — | US | disclosed |
| WO-2024056775-A1 | MACROCYCLIC LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-03-21 | — | — | WO | disclosed |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20210115049-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
| WO-2020132269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-2994469-B1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-9458145-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160075695-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| EP-2994469-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | Gilead Sciences, Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| WO-2015051043-A1 | BIARYL ACYL-SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051043-A1 | BIARYL ACYL-SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2014182929-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | USP1, UPP1, USP2 | CCR1 3631/4885CCR5 4716/4885CCR8 4386/4885 |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | SCN1A, SCN1B, SCN5A | CCR1 4557/4885CCR5 3897/4885CCR8 4597/4885 |
| US-20210115049-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, UPP1, USP2 | CCR1 3631/4885CCR5 4716/4885CCR8 4386/4885 |
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | LRRK2, PARK7, PINK1 | CCR1 4626/4885CCR5 3192/4885CCR8 4645/4885 |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, UPP1, USP2 | CCR1 3631/4885CCR5 4716/4885CCR8 4386/4885 |
| US-11958865-B1 | Leucine-rich repeat kinase 2 (LRRK2) inhibitors | LRRK2, PARK7, PINK1 | CCR1 4626/4885CCR5 3192/4885CCR8 4645/4885 |
| US-20160075695-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | CCR1 2326/4885CCR5 2322/4885CCR8 2919/4885 |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | CCR1 2327/4885CCR5 2376/4885CCR8 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.